1
|
Sunagawa Y, Tsukabe R, Irokawa Y, Funamoto M, Suzuki Y, Yamada M, Shimizu S, Katanasaka Y, Hamabe-Horiike T, Kawase Y, Naruta R, Shimizu K, Mori K, Hosomi R, Komiyama M, Hasegawa K, Morimoto T. Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice. Int J Mol Sci 2024; 25:2344. [PMID: 38397020 PMCID: PMC10889817 DOI: 10.3390/ijms25042344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 02/10/2024] [Accepted: 02/14/2024] [Indexed: 02/25/2024] Open
Abstract
Anserine, an imidazole dipeptide, is present in the muscles of birds and fish and has various bioactivities, such as anti-inflammatory and anti-fatigue effects. However, the effect of anserine on the development of heart failure remains unknown. We cultured primary cardiomyocytes with 0.03 mM to 10 mM anserine and stimulated them with phenylephrine for 48 h. Anserine significantly suppressed the phenylephrine-induced increases in cardiomyocyte hypertrophy, ANF and BNP mRNA levels, and histone H3K9 acetylation. An in vitro histone acetyltransferase (HAT) assay showed that anserine directly suppressed p300-HAT activity with an IC50 of 1.87 mM. Subsequently, 8-week-old male C57BL/6J mice were subjected to transverse aortic constriction (TAC) and were randomly assigned to receive daily oral treatment with anserine-containing material, Marine Active® (60 or 200 mg/kg anserine) or vehicle for 8 weeks. Echocardiography revealed that anserine 200 mg/kg significantly prevented the TAC-induced increase in left ventricular posterior wall thickness and the decrease in left ventricular fractional shortening. Moreover, anserine significantly suppressed the TAC-induced acetylation of histone H3K9. These results indicate that anserine suppresses TAC-induced systolic dysfunction, at least in part, by inhibiting p300-HAT activity. Anserine may be used as a pharmacological agent for human heart failure therapy.
Collapse
Affiliation(s)
- Yoichi Sunagawa
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
- Shizuoka General Hospital, Shizuoka 420-8527, Japan;
| | - Ryosuke Tsukabe
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Yudai Irokawa
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Masafumi Funamoto
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
- Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan
| | - Yuto Suzuki
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Miho Yamada
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Satoshi Shimizu
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Yasufumi Katanasaka
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
- Shizuoka General Hospital, Shizuoka 420-8527, Japan;
| | - Toshihide Hamabe-Horiike
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
- Shizuoka General Hospital, Shizuoka 420-8527, Japan;
| | - Yuto Kawase
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Ryuya Naruta
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
| | - Kana Shimizu
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Kiyoshi Mori
- Shizuoka General Hospital, Shizuoka 420-8527, Japan;
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Japan
- Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan
| | - Ryota Hosomi
- Laboratory of Food and Nutritional Sciences, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Osaka 564-8680, Japan;
| | - Maki Komiyama
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Koji Hasegawa
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Tatsuya Morimoto
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan; (Y.S.); (R.T.); (M.F.); (S.S.); (Y.K.); (T.H.-H.); (K.H.)
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan
- Shizuoka General Hospital, Shizuoka 420-8527, Japan;
| |
Collapse
|
2
|
Berdaweel IA, Monroe TB, Alowaisi AA, Mahoney JC, Liang IC, Berns KA, Gao D, McLendon JM, Anderson EJ. Iron scavenging and suppression of collagen cross-linking underlie antifibrotic effects of carnosine in the heart with obesity. Front Pharmacol 2024; 14:1275388. [PMID: 38348353 PMCID: PMC10859874 DOI: 10.3389/fphar.2023.1275388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Accepted: 11/13/2023] [Indexed: 02/15/2024] Open
Abstract
Oral consumption of histidyl dipeptides such as l-carnosine has been suggested to promote cardiometabolic health, although therapeutic mechanisms remain incompletely understood. We recently reported that oral consumption of a carnosine analog suppressed markers of fibrosis in liver of obese mice, but whether antifibrotic effects of carnosine extend to the heart is not known, nor are the mechanisms by which carnosine is acting. Here, we investigated whether oral carnosine was able to mitigate the adverse cardiac remodeling associated with diet induced obesity in a mouse model of enhanced lipid peroxidation (i.e., glutathione peroxidase 4 deficient mice, GPx4+/-), a model which mimics many of the pathophysiological aspects of metabolic syndrome and T2 diabetes in humans. Wild-type (WT) and GPx4+/-male mice were randomly fed a standard (CNTL) or high fat high sucrose diet (HFHS) for 16 weeks. Seven weeks after starting the diet, a subset of the HFHS mice received carnosine (80 mM) in their drinking water for duration of the study. Carnosine treatment led to a moderate improvement in glycemic control in WT and GPx4+/-mice on HFHS diet, although insulin sensitivity was not significantly affected. Interestingly, while our transcriptomic analysis revealed that carnosine therapy had only modest impact on global gene expression in the heart, carnosine substantially upregulated cardiac GPx4 expression in both WT and GPx4+/-mice on HFHS diet. Carnosine also significantly reduced protein carbonyls and iron levels in myocardial tissue from both genotypes on HFHS diet. Importantly, we observed a robust antifibrotic effect of carnosine therapy in hearts from mice on HFHS diet, which further in vitro experiments suggest is due to carnosine's ability to suppress collagen-cross-linking. Collectively, this study reveals antifibrotic potential of carnosine in the heart with obesity and illustrates key mechanisms by which it may be acting.
Collapse
Affiliation(s)
- Islam A. Berdaweel
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
- Department of Clinical Pharmacy, College of Pharmacy, Yarmouk University, Irbid, Jordan
| | - T. Blake Monroe
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
| | - Amany A. Alowaisi
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
- Department of Clinical Pharmacy, College of Pharmacy, Yarmouk University, Irbid, Jordan
| | - Jolonda C. Mahoney
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
| | - I-Chau Liang
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
| | - Kaitlyn A. Berns
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
| | - Dylan Gao
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
| | - Jared M. McLendon
- Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States
- Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Ethan J. Anderson
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States
- Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, United States
- Fraternal Order of Eagles Diabetes Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| |
Collapse
|
3
|
de Souza Gonçalves L, Pereira WR, da Silva RP, Yamaguchi GC, Carvalho VH, Vargas BS, Jensen L, de Medeiros MHG, Roschel H, Artioli GG. Anserine is expressed in human cardiac and skeletal muscles. Physiol Rep 2023; 11:e15833. [PMID: 37771070 PMCID: PMC10539627 DOI: 10.14814/phy2.15833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 09/12/2023] [Accepted: 09/12/2023] [Indexed: 09/30/2023] Open
Abstract
We evaluated whether anserine, a methylated analog of the dipeptide carnosine, is present in the cardiac and skeletal muscles of humans and whether the CARNMT1 gene, which encodes the anserine synthesizing enzyme carnosine-N-methyltransferase, is expressed in human skeletal muscle. We found that anserine is present at low concentrations (low micromolar range) in both cardiac and skeletal muscles, and that anserine content in skeletal muscle is ~15 times higher than in cardiac muscle (cardiac muscle: 10.1 ± 13.4 μmol·kg-1 of dry muscle, n = 12; skeletal muscle: 158.1 ± 68.5 μmol·kg-1 of dry muscle, n = 11, p < 0.0001). Anserine content in the heart was highly variable between individuals, ranging from 1.4 to 45.4 μmol·kg-1 of dry muscle, but anserine content was not associated with sex, age, or body mass. We also showed that CARNMT1 gene is poorly expressed in skeletal muscle (n = 10). This is the first study to demonstrate that anserine is present in the ventricle of the human heart. The presence of anserine in human heart and the confirmation of its expression in human skeletal muscle open new avenues of investigation on the specific and differential physiological functions of histidine dipeptides in striated muscles.
Collapse
Affiliation(s)
- Lívia de Souza Gonçalves
- Applied Physiology & Nutrition Research Group—Center of Lifestyle, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
- Division of PediatricsDepartment of PediatricsUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Wagner Ribeiro Pereira
- Applied Physiology & Nutrition Research Group—Center of Lifestyle, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Rafael Pires da Silva
- Applied Physiology & Nutrition Research Group—Center of Lifestyle, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Guilherme Carvalho Yamaguchi
- Applied Physiology & Nutrition Research Group—Center of Lifestyle, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | | | | | - Leonardo Jensen
- Laboratorio de Hipertensao do Instituto do Coraçao do Hospital das Clínicas da Faculdade de Medicina da Universidade São PauloSão PauloBrazil
| | | | - Hamilton Roschel
- Applied Physiology & Nutrition Research Group—Center of Lifestyle, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | | |
Collapse
|
4
|
Van der Stede T, Spaas J, de Jager S, De Brandt J, Hansen C, Stautemas J, Vercammen B, De Baere S, Croubels S, Van Assche CH, Pastor BC, Vandenbosch M, Van Thienen R, Verboven K, Hansen D, Bové T, Lapauw B, Van Praet C, Decaestecker K, Vanaudenaerde B, Eijnde BO, Gliemann L, Hellsten Y, Derave W. Extensive profiling of histidine-containing dipeptides reveals species- and tissue-specific distribution and metabolism in mice, rats, and humans. Acta Physiol (Oxf) 2023; 239:e14020. [PMID: 37485756 DOI: 10.1111/apha.14020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 06/26/2023] [Accepted: 07/13/2023] [Indexed: 07/25/2023]
Abstract
AIM Histidine-containing dipeptides (HCDs) are pleiotropic homeostatic molecules with potent antioxidative and carbonyl quenching properties linked to various inflammatory, metabolic, and neurological diseases, as well as exercise performance. However, the distribution and metabolism of HCDs across tissues and species are still unclear. METHODS Using a sensitive UHPLC-MS/MS approach and an optimized quantification method, we performed a systematic and extensive profiling of HCDs in the mouse, rat, and human body (in n = 26, n = 25, and n = 19 tissues, respectively). RESULTS Our data show that tissue HCD levels are uniquely produced by carnosine synthase (CARNS1), an enzyme that was preferentially expressed by fast-twitch skeletal muscle fibres and brain oligodendrocytes. Cardiac HCD levels are remarkably low compared to other excitable tissues. Carnosine is unstable in human plasma, but is preferentially transported within red blood cells in humans but not rodents. The low abundant carnosine analogue N-acetylcarnosine is the most stable plasma HCD, and is enriched in human skeletal muscles. Here, N-acetylcarnosine is continuously secreted into the circulation, which is further induced by acute exercise in a myokine-like fashion. CONCLUSION Collectively, we provide a novel basis to unravel tissue-specific, paracrine, and endocrine roles of HCDs in human health and disease.
Collapse
Affiliation(s)
- Thibaux Van der Stede
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
- Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark
| | - Jan Spaas
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
- University MS Center (UMSC) Hasselt, Pelt, Belgium
- BIOMED Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
| | - Sarah de Jager
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
| | - Jana De Brandt
- BIOMED Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
- REVAL Rehabilitation Research Center, Hasselt University, Hasselt, Belgium
| | - Camilla Hansen
- Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark
| | - Jan Stautemas
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
| | - Bjarne Vercammen
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
| | - Siegrid De Baere
- Department of Pathobiology, Pharmacology and Zoological Medicine, Ghent University, Ghent, Belgium
| | - Siska Croubels
- Department of Pathobiology, Pharmacology and Zoological Medicine, Ghent University, Ghent, Belgium
| | - Charles-Henri Van Assche
- The Maastricht MultiModal Molecular Imaging (M4I) institute, Maastricht University, Maastricht, The Netherlands
| | - Berta Cillero Pastor
- The Maastricht MultiModal Molecular Imaging (M4I) institute, Maastricht University, Maastricht, The Netherlands
| | - Michiel Vandenbosch
- The Maastricht MultiModal Molecular Imaging (M4I) institute, Maastricht University, Maastricht, The Netherlands
| | - Ruud Van Thienen
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
| | - Kenneth Verboven
- BIOMED Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
- REVAL Rehabilitation Research Center, Hasselt University, Hasselt, Belgium
| | - Dominique Hansen
- BIOMED Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
- REVAL Rehabilitation Research Center, Hasselt University, Hasselt, Belgium
- Heart Center Hasselt, Jessa Hospital Hasselt, Hasselt, Belgium
| | - Thierry Bové
- Department of Cardiac Surgery, Ghent University Hospital, Ghent, Belgium
| | - Bruno Lapauw
- Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - Charles Van Praet
- Department of Urology, Ghent University Hospital, Ghent, Belgium
- Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - Karel Decaestecker
- Department of Urology, Ghent University Hospital, Ghent, Belgium
- Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - Bart Vanaudenaerde
- Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| | - Bert O Eijnde
- University MS Center (UMSC) Hasselt, Pelt, Belgium
- SMRC Sports Medical Research Center, BIOMED Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
- Division of Sport Science, Stellenbosch University, Stellenbosch, South Africa
| | - Lasse Gliemann
- Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark
| | - Ylva Hellsten
- Department of Nutrition, Exercise and Sports, Copenhagen University, Copenhagen, Denmark
| | - Wim Derave
- Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium
| |
Collapse
|
5
|
Kong X, Wang C, Wu Q, Wang Z, Han Y, Teng J, Qi X. Screening and identification of key biomarkers of depression using bioinformatics. Sci Rep 2023; 13:4180. [PMID: 36914737 PMCID: PMC10010653 DOI: 10.1038/s41598-023-31413-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 03/11/2023] [Indexed: 03/14/2023] Open
Abstract
We aimed to identify the molecular biomarkers of MDD disease progression to uncover potential mechanisms of major depressive disorder (MDD). In this study, three microarray data sets, GSE44593, GSE12654, and GSE54563, were cited from the Gene Expression Omnibus database for performance evaluation. To perform molecular functional enrichment analyses, differentially expressed genes (DEGs) were identified, and a protein-protein interaction network was configured using the Search Tool for the Retrieval of Interacting Genes/Proteins and Cytoscape. To assess multi-purpose functions and pathways, such as signal transduction, plasma membrane, protein binding, and cancer pathways, a total of 220 DEGs, including 143 upregulated and 77 downregulated genes, were selected. Additionally, six central genes were observed, including electron transport system variant transcription factor 6, FMS-related receptor tyrosine kinase 3, carnosine synthetase 1, solute carrier family 22 member 13, prostaglandin endoperoxide synthetase 2, and protein serine kinase H1, which had a significant impact on cell proliferation, extracellular exosome, protein binding, and hypoxia-inducible factor 1 signaling pathway. This study enhances our understanding of the molecular mechanism of the occurrence and progression of MDD and provides candidate targets for its diagnosis and treatment.
Collapse
Affiliation(s)
- Xinru Kong
- Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China
| | - Chuang Wang
- Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China
| | - Qiaolan Wu
- Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China
| | - Ziyue Wang
- Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China
| | - Yu Han
- Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China
| | - Jing Teng
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, Shandong, China
| | - Xianghua Qi
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, Shandong, China.
| |
Collapse
|
6
|
Binding ability of L-carnosine towards Cu2+, Mn2+ and Zn2+ in aqueous solution. J Mol Liq 2022. [DOI: 10.1016/j.molliq.2022.120772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway. Molecules 2022; 27:molecules27144452. [PMID: 35889325 PMCID: PMC9324774 DOI: 10.3390/molecules27144452] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 07/01/2022] [Accepted: 07/04/2022] [Indexed: 11/17/2022] Open
Abstract
Different drug classes such as antineoplastic drugs (anthracyclines, cyclophosphamide, 5-fluorouracil, taxanes, tyrosine kinase inhibitors), antiretroviral drugs, antipsychotic, and immunosuppressant drugs are known to induce cardiotoxic and neurotoxic effects. Recent studies have demonstrated that the impairment of the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway is a primary event in the pathophysiology of drug-induced cardiotoxicity and neurotoxicity. The Nrf2 pathway regulates the expression of different genes whose products are involved in antioxidant and inflammatory responses and the detoxification of toxic species. Cardiotoxic drugs, such as the anthracycline doxorubicin, or neurotoxic drugs, such as paclitaxel, suppress or impair the Nrf2 pathway, whereas the rescue of this pathway counteracts both the oxidative stress and inflammation that are related to drug-induced cardiotoxicity and neurotoxicity. Therefore Nrf2 represents a novel pharmacological target to develop new antidotes in the field of clinical toxicology. Interestingly, carnosine (β-alanyl-l-histidine), an endogenous dipeptide that is characterized by strong antioxidant, anti-inflammatory, and neuroprotective properties is able to rescue/activate the Nrf2 pathway, as demonstrated by different preclinical studies and preliminary clinical evidence. Starting from these new data, in the present review, we examined the evidence on the therapeutic potential of carnosine as an endogenous antidote that is able to rescue the Nrf2 pathway and then counteract drug-induced cardiotoxicity and neurotoxicity.
Collapse
|
8
|
Creighton JV, de Souza Gonçalves L, Artioli GG, Tan D, Elliott-Sale KJ, Turner MD, Doig CL, Sale C. Physiological Roles of Carnosine in Myocardial Function and Health. Adv Nutr 2022; 13:1914-1929. [PMID: 35689661 PMCID: PMC9526863 DOI: 10.1093/advances/nmac059] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 04/25/2022] [Accepted: 06/08/2022] [Indexed: 01/28/2023] Open
Abstract
Carnosine is a pleiotropic histidine-containing dipeptide synthesized from β-alanine and l-histidine, with the intact dipeptide and constituent amino acids being available from the diet. The therapeutic application of carnosine in myocardial tissue is promising, with carnosine playing a potentially beneficial role in both healthy and diseased myocardial models. This narrative review discusses the role of carnosine in myocardial function and health, including an overview of the metabolic pathway of carnosine in the myocardial tissue, the roles carnosine may play in the myocardium, and a critical analysis of the literature, focusing on the effect of exogenous carnosine and its precursors on myocardial function. By so doing, we aim to identify current gaps in the literature, thereby identifying considerations for future research.
Collapse
Affiliation(s)
- Jade V Creighton
- Musculoskeletal Physiology Research Group, Sport, Health, and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, United Kingdom
| | | | - Guilherme G Artioli
- Department of Life Sciences, Manchester Metropolitan University, Manchester, United Kingdom
| | - Di Tan
- Natural Alternatives International, Inc., Carlsbad, CA, USA
| | - Kirsty J Elliott-Sale
- Musculoskeletal Physiology Research Group, Sport, Health, and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, United Kingdom,Department of Sport and Exercise Sciences, Institute of Sport, Manchester Metropolitan University, Manchester, United Kingdom
| | - Mark D Turner
- Centre for Diabetes, Chronic Diseases, and Ageing, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, United Kingdom
| | - Craig L Doig
- Centre for Diabetes, Chronic Diseases, and Ageing, School of Science and Technology, Nottingham Trent University, Clifton, Nottingham, United Kingdom
| | | |
Collapse
|
9
|
Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27103303. [PMID: 35630780 PMCID: PMC9143376 DOI: 10.3390/molecules27103303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 05/19/2022] [Indexed: 01/20/2023]
Abstract
Carnosine (β-alanyl-L-histidine) is a naturally occurring endogenous dipeptide and an over-the-counter food supplement with a well-demonstrated multimodal mechanism of action that includes the detoxification of reactive oxygen and nitrogen species, the down-regulation of the production of pro-inflammatory mediators, the inhibition of aberrant protein formation, and the modulation of cells in the peripheral (macrophages) and brain (microglia) immune systems. Since its discovery more than 100 years ago, a plethora of in vivo preclinical studies have been carried out; however, there is still substantial heterogeneity regarding the route of administration, the dosage, the duration of the treatment, and the animal model selected, underlining the urgent need for "coordinated/aligned" preclinical studies laying the foundations for well-defined future clinical trials. The main aim of the present position paper is to critically and concisely consider these key points and open a discussion on the possible "alignment" for future studies, with the goal of validating the full therapeutic potential of this intriguing molecule.
Collapse
|
10
|
Wang-Eckhardt L, Becker I, Wang Y, Yuan J, Eckhardt M. Absence of endogenous carnosine synthesis does not increase protein carbonylation and advanced lipoxidation end products in brain, kidney or muscle. Amino Acids 2022; 54:1013-1023. [PMID: 35294673 PMCID: PMC9217836 DOI: 10.1007/s00726-022-03150-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Accepted: 03/03/2022] [Indexed: 02/05/2023]
Abstract
Carnosine and other histidine-containing dipeptides are expected to be important anti-oxidants in vertebrates based on various in vitro and in vivo studies with exogenously administered carnosine or its precursor β-alanine. To examine a possible anti-oxidant role of endogenous carnosine, mice lacking carnosine synthase (Carns1−/−) had been generated and were examined further in the present study. Protein carbonylation increased significantly between old (18 months) and aged (24 months) mice in brain and kidney but this was independent of the Carns1 genotype. Lipoxidation end products were not increased in 18-month-old Carns1−/− mice compared to controls. We also found no evidence for compensatory increase of anti-oxidant enzymes in Carns1−/− mice. To explore the effect of carnosine deficiency in a mouse model known to suffer from increased oxidative stress, Carns1 also was deleted in the type II diabetes model Leprdb/db mouse. In line with previous studies, malondialdehyde adducts were elevated in Leprdb/db mouse kidney, but there was no further increase by additional deficiency in Carns1. Furthermore, Leprdb/db mice lacking Carns1 were indistinguishable from conventional Leprdb/db mice with respect to fasting blood glucose and insulin levels. Taken together, Carns1 deficiency appears not to reinforce oxidative stress in old mice and there was no evidence for a compensatory upregulation of anti-oxidant enzymes. We conclude that the significance of the anti-oxidant activity of endogenously synthesized HCDs is limited in mice, suggesting that other functions of HCDs play a more important role.
Collapse
Affiliation(s)
- Lihua Wang-Eckhardt
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Nussallee 11, 53115, Bonn, Germany
| | - Ivonne Becker
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Nussallee 11, 53115, Bonn, Germany
| | - Yong Wang
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Nussallee 11, 53115, Bonn, Germany
- Shandong Xinchuang Biotechnology Co., LTD, Jinan, China
| | - Jing Yuan
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Nussallee 11, 53115, Bonn, Germany
- College of Animal Science, Yangtze University, Jingzhou, Hubei, China
| | - Matthias Eckhardt
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Nussallee 11, 53115, Bonn, Germany.
| |
Collapse
|
11
|
Sato M, Nakamura S, Inada E, Takabayashi S. Recent Advances in the Production of Genome-Edited Rats. Int J Mol Sci 2022; 23:ijms23052548. [PMID: 35269691 PMCID: PMC8910656 DOI: 10.3390/ijms23052548] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/17/2022] [Accepted: 02/21/2022] [Indexed: 12/14/2022] Open
Abstract
The rat is an important animal model for understanding gene function and developing human disease models. Knocking out a gene function in rats was difficult until recently, when a series of genome editing (GE) technologies, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the type II bacterial clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated Cas9 (CRISPR/Cas9) systems were successfully applied for gene modification (as exemplified by gene-specific knockout and knock-in) in the endogenous target genes of various organisms including rats. Owing to its simple application for gene modification and its ease of use, the CRISPR/Cas9 system is now commonly used worldwide. The most important aspect of this process is the selection of the method used to deliver GE components to rat embryos. In earlier stages, the microinjection (MI) of GE components into the cytoplasm and/or nuclei of a zygote was frequently employed. However, this method is associated with the use of an expensive manipulator system, the skills required to operate it, and the egg transfer (ET) of MI-treated embryos to recipient females for further development. In vitro electroporation (EP) of zygotes is next recognized as a simple and rapid method to introduce GE components to produce GE animals. Furthermore, in vitro transduction of rat embryos with adeno-associated viruses is potentially effective for obtaining GE rats. However, these two approaches also require ET. The use of gene-engineered embryonic stem cells or spermatogonial stem cells appears to be of interest to obtain GE rats; however, the procedure itself is difficult and laborious. Genome-editing via oviductal nucleic acids delivery (GONAD) (or improved GONAD (i-GONAD)) is a novel method allowing for the in situ production of GE zygotes existing within the oviductal lumen. This can be performed by the simple intraoviductal injection of GE components and subsequent in vivo EP toward the injected oviducts and does not require ET. In this review, we describe the development of various approaches for producing GE rats together with an assessment of their technical advantages and limitations, and present new GE-related technologies and current achievements using those rats in relation to human diseases.
Collapse
Affiliation(s)
- Masahiro Sato
- Department of Genome Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan
- Correspondence: (M.S.); (S.T.); Tel.: +81-3-3416-0181 (M.S.); +81-53-435-2001 (S.T.)
| | - Shingo Nakamura
- Division of Biomedical Engineering, National Defense Medical College Research Institute, Saitama 359-8513, Japan;
| | - Emi Inada
- Department of Pediatric Dentistry, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan;
| | - Shuji Takabayashi
- Laboratory Animal Facilities & Services, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
- Correspondence: (M.S.); (S.T.); Tel.: +81-3-3416-0181 (M.S.); +81-53-435-2001 (S.T.)
| |
Collapse
|